Seamus Mulligan - 07 Aug 2025 Form 4 Insider Report for Jazz Pharmaceuticals plc (JAZZ)

Role
Director
Signature
By: /s/Adam Guttmann, as attorney in fact For: Seamus Mulligan
Issuer symbol
JAZZ
Transactions as of
07 Aug 2025
Net transactions value
$0
Form type
4
Filing time
11 Aug 2025, 17:32:47 UTC
Previous filing
13 May 2025
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"Seamus Mulligan filed Form 4 for Jazz Pharmaceuticals plc (JAZZ) on 11 Aug 2025."

Quick Takeaways

  • This page summarizes Seamus Mulligan's Form 4 filing for Jazz Pharmaceuticals plc (JAZZ).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Filing timestamp: 11 Aug 2025, 17:32.

What Changed

  • Previous filing in this sequence was filed on 13 May 2025.
  • Current net transaction value: $0.

Why This Matters

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Official SEC Source

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Mulligan Seamus Director 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN 4, IRELAND By: /s/Adam Guttmann, as attorney in fact For: Seamus Mulligan 11 Aug 2025 0001536639

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JAZZ Ordinary Shares Award $0 +3,507 +0.3% $0.000000 1,179,613 07 Aug 2025 Direct F1
holding JAZZ Ordinary Shares 101,621 07 Aug 2025 By Nerano Pharma Lim F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 24, 2026.
F2 Shares beneficially owned by Nerano Pharma Limited, an entity owned and controlled by the reporting person and his immediate family.

Sponsored